All News
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Read Article
Personalized Exercise may have Key Benefits in Axial Spondyloarthritis
In a very interesting study at #EULAR2024, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for individuals with axial spondyloarthritis (axSpA) and severe functional limitations. This finding marks a critical advancement in the treatment of axSpA, particularly for patients with sustained disease activity, severe ankylosis, or significant comorbidities, who have historically been under-represented in research.
Read Article
Achieving drug-free remission in axSpA
EurekAlert!
A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients.
Read Article
Axial & Psoriatic Disease
Dr. Peter Nash at Eular 2024 in Vienna, Austria.
https://t.co/eHfNQgN1BQ https://t.co/Uj6AwbXj8J
Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA.
https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G
Dr. John Cush RheumNow ( View Tweet)
Lit. cohort analysis of >330K #AS shows higher risk of cancer (RR=1.16: 1.07–1.26); w/ higher risk in Asia, but not Europe. Increased CA risk for : bone (RR 3.41), thyroid(1.76), myeloma (1.74), leukemia (1.52), kidney (1.45), prostate (1.43), NHL (1.42) https://t.co/disRefur0l https://t.co/ffjED0Ftvc
Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA.
https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13
Dr. John Cush RheumNow ( View Tweet)
Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024
Dr. John Cush RheumNow ( View Tweet)
In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/bVYjnBqpaf
Links:
Dr. John Cush RheumNow ( View Tweet)
SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085
Dr. John Cush RheumNow ( View Tweet)
Be-GIANT cohort, 44.3% pts met definition of early axSpA (<2 yr Sxs). early axSpA had younger age and lower frequency of radiographic sacroiliitis. MDs think early disease to be more severe with higher physician global than late axSpA @synovialjoints #EULAR2024 Abstract POS0443 https://t.co/97J9tg0XZg
Dr. John Cush RheumNow ( View Tweet)
Work ability impaired in majority of axSpA measured by the WAI score. 996 pts w a mean WAI score of 31.7. Overall, 28%/43%pts were in poor/moderate work ability, older, more often obese, w/ lower education, & phys work @synovialjoints #EULAR2024 Abstract POS0437
@RheumNow https://t.co/rQ4BunCn6T
Dr. John Cush RheumNow ( View Tweet)
Personalized Exercise may have Key Benefits in AxSpa
At EULAR, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for people with AxSpA and severe functional limitations.
https://t.co/TUP6hoLgJ4 https://t.co/t1gNQBdFzh
Dr. John Cush RheumNow ( View Tweet)
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
https://t.co/mv9DeZ9cez https://t.co/1OpT3MomO8
Dr. John Cush RheumNow ( View Tweet)
Achieving drug-free remission in axSpA
In early axSpA, over 60% achieved sustained inactive disease. Male, non-smokers, low BASDAI scores had higher remission rates. Drug-free remission remains challenging.
https://t.co/Yv8a8C1hc9 https://t.co/JaYvfGry4P
Dr. John Cush RheumNow ( View Tweet)
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa
Retrospective study in French THIN database
Diagnostic delay remains common
Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain
#EULAR2024 @DrMiniDey https://t.co/egwDL1XjSw
Dr. John Cush RheumNow ( View Tweet)
Treat to Target Outcomes in Early AxSpA
Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
https://t.co/1svlH2GW9W https://t.co/oT1ZOPdR8e
Dr. John Cush RheumNow ( View Tweet)
Does Telemonitoring in SpA Work?
Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
https://t.co/UUmnsAdx0t https://t.co/NE36OtKBwK
Dr. John Cush RheumNow ( View Tweet)
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.
https://t.co/hYy7Wg2GMJ https://t.co/GVjtf89c3t
Dr. John Cush RheumNow ( View Tweet)
Inflammatory bowel disease in spondyloarthritis - does it matter?
Do the clinical features of axSpA patients with and without IBD differ?
https://t.co/t0wJRXXH0a https://t.co/iZsiP1AgWh
Dr. John Cush RheumNow ( View Tweet)
